Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A Century of Schizophrenia: One Disorder or Many?

2.

Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer

3.

Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.

4.

Mental health risk persists years after cancer diagnosis

5.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot